Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized dose-titration study of ralfinamide for neuropathic pain
2004-000557-35Phase 2Completed
- Sponsor
- Newron Pharmaceuticals
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Neuralgia comparing Ralfinamide ascending-dose with Placebo (2 arms). Primary endpoint: Clinical tolerability and maximum tolerated dose of ralfinamide. Started Feb 2005; status: completed.
02
Drugs
ralfinamide
03
Conditions
Neuralgia
Beyond the preview
Go deeper on 2004-000557-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000557-35.